

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1 (original). A method of a treating a patient for a neuro-degenerative disorder comprising administering to that patient a therapeutically effective amount of one or more of D- $\beta$ -hydroxybutyric acid, acetoacetate, or a metabolic precursor or physiologically acceptable salt of D- $\beta$ -hydroxybutyric acid or acetoacetate, such as to elevate the patient's blood level of ketone bodies, defined as the sum total of D- $\beta$ -hydroxybutyric acid and acetoacetate, to a therapeutic level effective to treat the disorder

wherein when a metabolic precursor is administered it is not hydroxybutyryl carnitine.

2 (original). A method of treating a patient in order to treat a neuro-degenerative disorder comprising administering to that patient a therapeutically effective amount of at least one of D- $\beta$ -hydroxybutyric acid, acetoacetate, or a metabolic precursor or physiologically acceptable salt of D- $\beta$ -hydroxybutyric acid or acetoacetate, such as to elevate the patient's blood level of ketone bodies, defined as the sum total of D- $\beta$ -hydroxybutyric acid and acetoacetate, to a therapeutic level effective to treat the disorder

wherein the patient's blood level is elevated to from 0.3mM to 20mM.

3 (original). A method of treating a CNS cell, peripheral nerve cell, or otherwise insulin insensitive cell in need of therapy for one or more of neuro-degeneration, GABA preventable seizure, or insufficient ability to metabolise glucose, comprising administering to that cell one or more compounds selected from the group consisting of D- $\beta$ -hydroxybutyric acid, acetoacetate, compounds which are oligomers of D- $\beta$ -hydroxybutyric acid, acetoacetyl esters of D- $\beta$ -hydroxybutyric acid and acetoacetyl esters of oligomers of D- $\beta$ -hydroxybutyric acid, and physiologically acceptable salts thereof.

4 (original). A method of treating an patient for epilepsy, diabetes or an insulin resistant state comprising administering to that patient a therapeutically effective amount of one or more compounds selected from the group consisting of D- $\beta$ -hydroxybutyric acid, acetoacetate and metabolic precursors of D- $\beta$ -hydroxybutyric acid or acetoacetate which comprise moieties selected from the group consisting of R-1,3-butandiol, acetoacetyl and D- $\beta$ -hydroxybutyryl moieties and physiologically acceptable salts and esters thereof.

5 (currently amended). A method as claimed in ~~any one of Claim 1, Claim 2, Claim 3 and Claim 4~~ Claim 1 wherein on administration of the compound to an unfasted patient in need of such therapy, the blood level of ketone bodies, defined as the sum total of D-3-hydroxybutyric acid and acetoacetate, is raised to between 0.3 and 20mM.

6 (currently amended). A method as claimed in Claim 1 ~~or Claim 2~~ wherein

the neurodegenerative disorder is selected from the group consisting of neurodegenerative disorders involving inability to metabolise glucose, memory loss in ageing, neurotoxic peptides or proteins, and genetic abnormality.


7 (original). A method as claimed in Claim 6 wherein the neurodegenerative disorder is selected from those involving neurotoxic protein plaques.

8 (currently amended). A method as claimed in Claim 1 ~~or Claim 2~~ wherein the metabolic precursor is selected from the group consisting of Free Fatty Acids and compounds comprising 1,3-butanediol, acetoacetyl or D- $\beta$ -hydroxybutyryl moieties.


9 (currently amended). A method as claimed in Claim 1, ~~Claim 2, Claim 3 or Claim 4~~ wherein the metabolic precursor is a polymer or oligomer of D- $\beta$ -hydroxybutyrate.

10 (original). A method as claimed in Claim 9 wherein the metabolic precursor is an acetoacetyl ester.

11 (original). A method as claimed in Claim 9 wherein metabolic precursor is selected from the group consisting of compounds of general formulae



and



or physiological acceptable salts or esters thereof


wherein in each case n is selected such that the polymer or oligomer is readily metabolised on administration to a human or animal body to provide elevated ketone body levels in blood.

12 (original). A method as claimed in Claim 11 wherein n is an integer of 0 to 1,000.

13 (original). A method as claimed in Claim 11 wherein n is an integer of from 1 to 5.

14 (currently amended). A method as claimed in Claim 1, ~~Claim 2, Claim 3 or Claim 4~~ wherein the level of ketone bodies produced in the blood is in the ratio 1:1 to 20:1 of D- $\beta$ -hydroxybutyrate to acetoacetate.

15 (original). A method as claimed in Claim 9 wherein the oligomer is a cyclic oligomer of formula



where n is an integer of 1 or more


or a complex thereof with one or more cations or a salt thereof

16 (original). A method as claimed in Claim 15 wherein the one or more cations are selected from the group consisting of sodium, potassium, magnesium and calcium.

17 (currently amended). A method as claimed in Claim 15 wherein n is an integer from 1 to ~~to~~ 20.

18 (original). A method as claimed in Claim 1 wherein it is (R, R, R)-4, 8, 12-trimethyl-1, 5, 9-trioxadodeca-2, 6, 10-trione.

19 (original). A compound of formula



or physiological acceptable salts or esters thereof.

wherein  $n$  is an integer from 0 to 1000

20 (currently amended). A compound as defined in Claim 19 wherein the ester is selected from the group consisting of monohydric, dihydric or trihydric alcohol esters.

21 (original). A compound as claimed in Claim 19 wherein the ester is of (R)-1,3-butandiol.

22 (original). A compound as claimed in Claim 19 wherein  $n$  is selected from the group of integers 0, 1, 2, 3 and 4.

23 (original). A foodstuff comprising poly D-β-hydroxybutyrate characterised in that it is derived from a foodstuff generating organism that has had a gene capable of producing D-β-hydroxybutyrate inserted therein.

24 (original). A foodstuff characterised in that it comprises at least 5% ketone bodies by weight.

25 (original). A method for the synthesis of D- $\beta$ -hydroxybutyryl-acetoacetate or poly or oligo-D- $\beta$ -hydroxybutyryl-acetoacetate esters comprising the reaction of acetoacetic acid halide with D- $\beta$ -hydroxybutyrate or poly- or oligo-D- $\beta$ -hydroxybutyrate.

26 (original). A method for synthesis of D- $\beta$ -hydroxybutyryl-acetoacetate or oligo-D- $\beta$ -hydroxybutyryl-acetoacetate comprising reacting D- $\beta$ -hydroxybutyric acid with diketene.

27 (original). A method of synthesising an oligomer of D- $\beta$ -hydroxybutyric acid comprising heating a solution of D- $\beta$ -hydroxybutyric acid in a solvent until an oligomer of a desired number of repeats is produced.

28 (currently amended). Use of D- $\beta$ -hydroxybutyric acid, acetoacetate, or a metabolic precursor or physiologically acceptable salt of D- $\beta$ -hydroxybutyric acid or acetoacetate for the manufacture of a medicament for the treatment of a disorder by a method as set out in ~~any one of Claims 1 to 14~~ Claim 1 provided that when the use is of a metabolic precursor that is not racemic hydroxybutyryl carnitine.

29 (currently amended). A foodstuff as claimed in Claim 23 ~~or Claim 24~~ for use

in therapy.

30 (currently amended). Poly-D- $\beta$ -hydroxybutyrate for use in therapy.

31 (currently amended). A composition comprising a compound selected from those claimed in ~~any one of Claims 15 to 18~~ Claim 15 and poly D- $\beta$ -hydroxybutyrate together with a physiologically acceptable carrier, in sterile and pyrogen free form.